Medifast (MED) Stock Price

Medifast Price

NYSE·CLOSED
9.83USD-0.08 (-0.81 %)
Market closed

Revenue has compounded at 9.1% per year over the past 19 years to 385.79 M USD. Earnings per share have declined at 4.0% per year over the last 18 years. Medifast's net margin stands at -4.8%, down from 10.7% several years earlier. Medifast currently offers a dividend yield of about 50.36%. The payout ratio is around 54% of earnings. The dividend has grown at 45.2% per year over the past 8 years. Analysts set a median price target of 15.30 USD, implying 55.6% above the current price. Of 9 analysts, 0 rate the stock a buy — an overall Sell consensus. The stock trades about 4% above its 52-week low.

Medifast stock price

Volume
Ex-Dividend
Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Medifast over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Medifast stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Medifast's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Medifast Stock Price History
DateMedifast Price
7/31/20269.83 USD
7/30/20269.91 USD
7/29/20269.58 USD
7/27/20269.62 USD
7/23/20269.45 USD
7/22/20269.76 USD
7/21/202610.52 USD
7/20/202610.38 USD
7/17/202610.26 USD
7/16/202610.50 USD
7/15/202610.63 USD
7/14/202610.61 USD
7/13/202610.82 USD
7/10/202610.72 USD
7/9/202610.68 USD
7/8/202610.59 USD
7/7/202610.89 USD
7/6/202610.96 USD
7/2/202610.96 USD
7/1/202611.03 USD
6/30/202610.61 USD
6/29/202610.70 USD
6/26/202610.51 USD
6/25/202610.20 USD
6/24/202610.36 USD
6/23/202610.62 USD
6/22/202611.52 USD
6/18/202611.04 USD
6/17/202611.25 USD
6/16/202611.27 USD
6/15/202611.94 USD
6/12/202611.89 USD
6/11/202611.92 USD
6/10/202612.14 USD
6/9/202612.18 USD
6/8/202612.07 USD
6/5/202612.10 USD
6/4/202612.27 USD
6/3/202612.24 USD
6/2/202612.36 USD
6/1/202612.70 USD
5/29/202612.53 USD
5/28/202613.15 USD
5/27/202612.72 USD
5/26/202613.09 USD
5/22/202612.59 USD
5/21/202612.63 USD
5/20/202612.60 USD
5/19/202612.59 USD
5/18/202612.45 USD
5/15/202612.48 USD
5/14/202612.59 USD
5/13/202612.48 USD
5/12/202612.57 USD
5/11/202612.40 USD
5/8/202612.59 USD
5/7/202612.69 USD
5/6/202612.69 USD
5/5/202613.02 USD
5/4/202610.63 USD
4/22/202610.95 USD
4/21/202611.05 USD
4/20/202610.92 USD
4/17/202610.96 USD
4/16/202610.87 USD
4/15/202610.85 USD
4/14/202610.88 USD
4/13/202610.63 USD
4/10/202610.06 USD
4/9/202610.21 USD
4/8/202610.22 USD
4/7/202610.20 USD
4/6/202610.52 USD
4/2/202610.36 USD
4/1/202610.10 USD
3/31/202610.19 USD
3/30/20269.99 USD
3/27/20269.92 USD
3/26/20269.75 USD
3/25/20269.63 USD
3/24/20269.59 USD
3/23/20269.59 USD
3/22/202610.10 USD
3/20/202610.00 USD
3/19/202610.00 USD
3/18/202610.07 USD
3/17/202610.10 USD
3/16/202610.05 USD
3/15/202610.05 USD
3/13/20269.62 USD
3/12/20269.62 USD
3/11/20269.53 USD
3/10/202610.12 USD
3/9/202610.73 USD
3/8/202610.67 USD
3/6/202610.77 USD
3/5/202610.77 USD
3/4/202610.80 USD
3/3/202610.71 USD
3/2/202610.46 USD
3/1/202610.44 USD
2/27/202610.53 USD
2/26/202610.53 USD
2/25/202610.43 USD
2/24/202610.65 USD
2/23/202610.48 USD
2/22/202610.60 USD
2/20/202610.63 USD
2/19/202610.63 USD
2/18/202610.62 USD
2/17/202610.71 USD
2/16/202610.80 USD
2/13/202610.77 USD
2/12/202610.77 USD
2/11/202610.81 USD
2/10/202610.85 USD
2/9/202611.14 USD
2/8/202611.30 USD
2/6/202611.36 USD
2/5/202611.36 USD
2/4/202610.83 USD
2/3/202611.14 USD
2/2/202611.01 USD
2/1/202611.50 USD
1/30/202611.44 USD
1/29/202611.44 USD
1/28/202611.15 USD
1/27/202611.19 USD
1/26/202611.46 USD
1/25/202612.00 USD
1/23/202612.05 USD
1/22/202612.05 USD
1/21/202611.70 USD
1/20/202611.80 USD
1/19/202611.66 USD
1/16/202611.82 USD
1/15/202611.82 USD
1/14/202611.83 USD
1/13/202611.68 USD
1/12/202611.80 USD
1/11/202611.69 USD
1/9/202611.42 USD
1/8/202611.42 USD
1/7/202611.03 USD
1/6/202610.69 USD
1/5/202610.83 USD
1/4/202610.95 USD
1/2/202610.40 USD
1/1/202610.40 USD
12/31/202510.68 USD
12/30/202510.68 USD
12/29/202510.54 USD
12/28/202510.54 USD
12/26/202511.04 USD
12/25/202511.04 USD
12/24/202511.28 USD
12/23/202511.28 USD
12/22/202511.15 USD
12/21/202511.33 USD
12/19/202511.85 USD
12/18/202511.85 USD
12/17/202512.03 USD
12/16/202512.18 USD
12/15/202512.03 USD
12/14/202512.00 USD
12/12/202512.36 USD
12/11/202512.36 USD
12/10/202511.83 USD
12/9/202511.66 USD
12/8/202511.30 USD
12/7/202511.36 USD
12/5/202510.88 USD
12/4/202510.88 USD
12/3/202510.86 USD
12/2/202511.01 USD
12/1/202510.99 USD
11/30/202510.74 USD
11/28/202510.97 USD
11/27/202510.97 USD
11/26/202510.97 USD
11/25/202510.97 USD
11/24/202510.91 USD
11/23/202510.59 USD
11/21/202510.68 USD
11/20/202510.68 USD
11/19/202510.42 USD
11/18/202510.77 USD
11/17/202511.18 USD
11/16/202511.10 USD
11/14/202511.38 USD
11/13/202511.38 USD
11/12/202511.46 USD
11/11/202511.63 USD
11/10/202511.65 USD
11/9/202511.79 USD
11/7/202511.93 USD
11/6/202511.93 USD
11/5/202511.80 USD
11/4/202512.18 USD
11/3/202511.98 USD
11/2/202511.88 USD
10/31/202512.02 USD
10/30/202512.02 USD
10/29/202512.14 USD
10/28/202512.18 USD
10/27/202512.73 USD
10/26/202512.72 USD
10/23/202512.54 USD
10/22/202512.48 USD
10/21/202512.64 USD
10/20/202512.87 USD
10/19/202512.72 USD
10/16/202512.92 USD
10/15/202512.86 USD
10/14/202513.17 USD
10/13/202513.27 USD
10/12/202513.26 USD
10/9/202513.27 USD
10/8/202514.03 USD
10/7/202514.02 USD
10/6/202513.86 USD
10/5/202513.95 USD
10/2/202513.99 USD
10/1/202513.67 USD
9/30/202513.57 USD
9/29/202513.67 USD
9/28/202513.84 USD
9/25/202513.71 USD
9/24/202513.65 USD
9/23/202513.83 USD
9/22/202514.06 USD
9/21/202514.32 USD
9/18/202514.35 USD
9/17/202514.57 USD
9/16/202514.13 USD
9/15/202514.36 USD
9/14/202514.22 USD
9/11/202513.97 USD
9/10/202513.92 USD
9/9/202513.81 USD
9/8/202513.80 USD
9/7/202513.82 USD
9/4/202513.55 USD
9/3/202513.85 USD
9/2/202513.96 USD
9/1/202513.92 USD
8/28/202514.03 USD
8/27/202514.02 USD
8/26/202514.26 USD
8/25/202513.97 USD
8/24/202514.09 USD
8/21/202514.29 USD
8/20/202513.57 USD
8/19/202513.65 USD
8/18/202514.15 USD
8/17/202513.38 USD
8/14/202513.19 USD
8/13/202513.03 USD
8/12/202513.70 USD
8/11/202513.19 USD
8/10/202512.83 USD
8/7/202512.85 USD
8/6/202512.74 USD
8/5/202512.96 USD
8/4/202513.07 USD
8/3/202513.51 USD
Access this data via the Eulerpool API

Medifast Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2020
934.84 M USD
134.16 M USD
102.86 M USD
Jan 1, 2021
1.53 B USD
216.24 M USD
164.03 M USD
Jan 1, 2022
1.60 B USD
184.81 M USD
143.57 M USD
Jan 1, 2023
1.07 B USD
126.40 M USD
99.42 M USD
Jan 1, 2024
602.46 M USD
2.88 M USD
2.09 M USD
Jan 1, 2025
385.79 M USD
-14.21 M USD
-18.67 M USD
Jan 1, 2026 (e)
279.70 M USD
20.64 M USD
-20.28 M USD
Jan 1, 2027 (e)
256.00 M USD
18.89 M USD
-6.58 M USD

Medifast Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 3, 2026, 2:31 PM
 
REVENUEB USD
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB USD
EBITM USD
EBIT MARGIN%
NET INCOMEM USD
NET INCOME GROWTH%
DIV.USD
DIV. GROWTH%
SHARESM
201220132014201520162017201820192020202120222023202420252026e2027e
0.360.360.290.270.270.300.500.710.931.531.601.070.600.390.280.26
19.46-19.94-4.560.749.8566.4542.3231.0063.384.72-32.92-43.84-36.05-27.53-8.24
75.2875.0073.3373.9074.8275.4275.6575.1874.6373.8571.3472.2973.7571.4371.4371.43
0.270.270.210.200.210.230.380.540.701.131.140.780.440.280.200.18
23.0033.0030.0028.0026.0039.0069.0091.00134.00216.00184.00126.002.00-14.0020.0018.00
6.469.2710.5310.299.4912.9613.7712.7614.3514.1511.5111.750.33-3.647.177.03
15.0023.0013.0020.0017.0027.0055.0077.00102.00164.00143.0099.002.00-18.00-20.00-6.00
-16.6753.33-43.4853.85-15.0058.82103.7040.0032.4760.78-12.80-30.77-97.98-1,000.0011.11-70.00
1.001.071.442.193.384.525.686.566.607.929.50
7.0034.5852.0854.3433.7325.6615.490.6119.95
13.8313.1612.1711.9012.0012.1512.0111.9511.8711.7911.0910.9410.9810.9910.9910.99
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Medifast generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Medifast retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Medifast's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Medifast has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Medifast's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Medifast stock margins

The Medifast margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medifast. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medifast.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
74.65 %
14.35 %
11.00 %
Jan 1, 2021
73.89 %
14.17 %
10.75 %
Jan 1, 2022
71.34 %
11.56 %
8.98 %
Jan 1, 2023
72.37 %
11.79 %
9.27 %
Jan 1, 2024
73.80 %
0.48 %
0.35 %
Jan 1, 2025
71.33 %
-3.68 %
-4.84 %
Jan 1, 2026 (e)
71.33 %
7.38 %
-7.25 %
Jan 1, 2027 (e)
71.33 %
7.38 %
-2.57 %

Medifast Stock Revenue, EBIT, Earnings per Share

The Medifast earnings per share therefore indicates how much revenue Medifast has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
78.75 USD
11.30 USD
8.66 USD
Jan 1, 2021
129.49 USD
18.35 USD
13.92 USD
Jan 1, 2022
144.18 USD
16.67 USD
12.95 USD
Jan 1, 2023
98.04 USD
11.56 USD
9.09 USD
Jan 1, 2024
54.85 USD
0.26 USD
0.19 USD
Jan 1, 2025
35.10 USD
-1.29 USD
-1.70 USD
Jan 1, 2026 (e)
25.51 USD
1.88 USD
-1.85 USD
Jan 1, 2027 (e)
23.35 USD
1.72 USD
-0.60 USD

Medifast business model & stock analysis

Medifast Inc. is a leading provider of health and wellness solutions, with its headquarters in Baltimore, Maryland. The company was founded in 1980 by Dr. William Vitale and has since experienced continuous growth. Medifast's nutrition and health products are available in the United States, Canada, and Puerto Rico.

Medifast SWOT Analysis

Strengths

Medifast Inc has several strengths that contribute to its success in the market.

  • Strong brand recognition and reputation.
  • Well-established distribution network.
  • Diverse range of products and services.
  • Proven track record of customer satisfaction.
  • Effective marketing strategies.

Weaknesses

Despite its strengths, Medifast Inc also faces certain weaknesses that need to be addressed.

  • Dependency on a limited number of suppliers.
  • Relatively high pricing compared to competitors.
  • Inadequate international presence.
  • Limited product diversification within certain segments.

Opportunities

Medifast Inc has several opportunities in the market that can drive its future growth.

  • Increasing consumer awareness and demand for health-focused products.
  • Growing population of individuals seeking weight management solutions.
  • Potential partnerships with complementary businesses.
  • Expansion into untapped international markets.
  • Technological advancements enabling efficient product development and delivery.

Threats

Medifast Inc must be aware of potential threats that could impact its business negatively.

  • Intense competition from both traditional and emerging players.
  • Government regulations and policies affecting the health and wellness industry.
  • Economic downturns leading to decreased consumer spending.
  • Shifts in consumer preferences towards alternative weight management methods.
  • Negative publicity or product quality issues affecting brand perception.

Medifast Employees

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Medifast Employees
Details
Date
Medifast Employees
Jan 1, 2018
- Employees
Jan 1, 2019
- Employees
Jan 1, 2020
- Employees
Jan 1, 2021
- Employees
Jan 1, 2022
- Employees
Jan 1, 2023
- Employees
Jan 1, 2024
- Employees
Jan 1, 2025
- Employees

Medifast Segments

Medifast Eulerpool Fair Value

Details

Fair Value Estimate

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Medifast historical P/E ratio, EBIT multiple, and P/S ratio

Medifast annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Medifast shares outstanding

The number of shares of Medifast was 10.99 M in 2025. This indicates how many shares Medifast is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
11.87 M Stocks
Jan 1, 2021
11.79 M Stocks
Jan 1, 2022
11.09 M Stocks
Jan 1, 2023
10.94 M Stocks
Jan 1, 2024
10.98 M Stocks
Jan 1, 2025
10.99 M Stocks
Jan 1, 2026 (e)
10.99 M Stocks
Jan 1, 2027 (e)
10.99 M Stocks

Medifast Dividend History

9 years of dividend payments

YearAnnual DividendYoY ChangePayments
20234.95USD 24.5%
20226.56USD 15.5%
20215.68USD 25.7%
20204.52USD 33.7%
20193.38USD 54.3%
20182.19USD 52.1%
20171.44USD 34.6%
20161.07USD 328.0%
20150.25USD

Medifast dividend payout ratio

In 2025, Medifast had a payout ratio of 51.25%. The payout ratio indicates the percentage of the company's profits that Medifast distributes as dividends.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
52.17 %
Jan 1, 2021
40.81 %
Jan 1, 2022
50.66 %
Jan 1, 2023
54.45 %
Jan 1, 2024
48.64 %
Jan 1, 2025
51.25 %
Jan 1, 2026 (e)
51.44 %
Jan 1, 2027 (e)
50.44 %

Current Medifast forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
0.00 % (0)
Hold
44.44 % (4)
Sell
55.56 % (5)
12M Price Target
15.30
Last Price
9.83
Currency
USD
12M Return Potential
55.65 %
LTM Return
0 %

Medifast Analyst Rating Actions

DateFirmActionRatingReliability
2/19/2026
Stephens & Co.
Stephens & Co.
MaintainedEqual Weight
2/19/2025
DA Davidson
DA Davidson
MaintainedNeutral
11/5/2024
DA Davidson
DA Davidson
UpgradeUnderperformNeutral
7/22/2024
DA Davidson
DA Davidson
MaintainedUnderperform
6/5/2024
DA Davidson
DA Davidson
DowngradeNeutralUnderperform
4/30/2024
DA Davidson
DA Davidson
MaintainedNeutral
2/21/2024
DA Davidson
DA Davidson
MaintainedNeutral
8/8/2023
DA Davidson
DA Davidson
MaintainedNeutral
7/31/2023
DA Davidson
DA Davidson
MaintainedNeutral
5/2/2023
DA Davidson
DA Davidson
MaintainedNeutral

Eulerpool Reliability Score (0–100): measures how often a firm’s bullish or bearish calls were directionally correct three months later, blended with the average return following its calls. Every rating we record is stored permanently and scores update continuously; firms with fewer than 3 measured calls are not scored yet.

Medifast Earnings Estimates & Surprises

DateEPS estimateEPS ActualRevenue EstimatePrice reactionQuarterly report
8/10/2026-0.66USD-73.43 MUSD-2026 Q2
5/4/2026-0.53USD-69.89 MUSD-2026 Q1
2/24/2026-0.83USD-74.54 MUSD-2025 Q4
4/29/20241.96USD-219.27 MUSD-2024 Q1
2/19/20240.91USD-185.99 MUSD-2023 Q4
8/1/20233.88USD-410.87 MUSD-2023 Q2
5/1/20233.29USD-379.91 MUSD-2023 Q1
2/21/20232.24USD-335.05 MUSD-2022 Q4
11/3/20221.93USD-354.54 MUSD-2022 Q3
8/3/20223.27USD-454.57 MUSD-2022 Q2
...

EESG©

Eulerpool ESG Scorecard© for the Medifast stock

30/100
8
Environment
38
Social
44
Governance
E

Environment

20
Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medifast shareholder structure

% Name
7.41868%
Renaissance Technologies LLC
Renaissance Technologies LLC
7.29061%
BlackRock Institutional Trust Company, N.A.
BlackRock Institutional Trust Company, N.A.
7.25574%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
3.84173%
Charles Schwab Investment Management, Inc.
Charles Schwab Investment Management, Inc.
3.82213%
Two Sigma Investments, LP
Two Sigma Investments, LP
3.74990%
Acadian Asset Management LLC
Acadian Asset Management LLC
...

Medifast Beneficial Ownership Filings (SEC 13D/G)

Free Float
69.7%
Float Shares
-
Shares Outstanding
-
StakeHolderFiling
50.00%
James Cassidy
James Cassidy
SEC ↗
17.20%
(1) BlackRock, Inc.
(1) BlackRock, Inc.
SEC ↗
13.97%
04-2683227
04-2683227
SEC ↗
12.91%
The Vanguard Group - 23-1945930
The Vanguard Group - 23-1945930
SEC ↗
9.70%
2
2
SEC ↗
9.40%
#39-1078128
#39-1078128
SEC ↗
8.50%
RNI-NV LIMITED PARTNERSHIP
RNI-NV LIMITED PARTNERSHIP
SEC ↗
8.03%
13-3127734
13-3127734
SEC ↗
7.96%
William H. Miller III Living Trust (the "Trust")
William H. Miller III Living Trust (the "Trust")
SEC ↗
7.96%
Miller Value Partners, LLC
Miller Value Partners, LLC
SEC ↗

Medifast Executives and Management Board

13 members · avg. age 58 · 23 % women

DC

Mr. Daniel Chard (60)

Chairman of the Board, Chief Executive Officer · since 2016

5.61 M USD

Management

JM

Mr. James Maloney (57)

Chief Financial Officer

1.35 M USD
NJ

Mr. Nicholas Johnson (45)

Chief Field Operations Officer

1.13 M USD
JG

Mr. Jason Groves (54)

Chief Legal Officer, Corporate Secretary · since 2009

1.09 M USD
AT

Mr. Anthony Tyree (60)

Chief Marketing Officer, Chief Business Operations

1.07 M USD
CG

Ms. Claudia Greninger (52)

Chief Human Resources Officer

JM

Mr. Jonathan Mackenzie (54)

Chief Accounting Officer, Vice President - Finance

Board of Directors

JB

Mr. Jeffrey Brown (64)

Lead Independent Director

250,359.00 USD
SS

Mr. Scott Schlackman (67)

Independent Director

225,614.00 USD
AT

Ms. Andrea Thomas (60)

Independent Director

223,114.00 USD
MH

Mr. Michael Hoer (70)

Independent Director

218,114.00 USD
MX

Mr. Ming Xian (61)

Independent Director

208,663.00 USD
EG

Ms. Elizabeth Geary (44)

Independent Director

205,614.00 USD

Frequently asked questions about Medifast

Medifast Inc. operates under a direct selling business model, providing weight management and health products. This company offers various weight loss programs, including their popular Optavia brand. Medifast sells its products through a network of independent distributors and coaches, who assist individuals in achieving their health and wellness goals. By emphasizing the importance of nutrition, portion control, and regular exercise, Medifast aims to help customers maintain a healthier lifestyle. With its extensive product line and dedicated network of distributors, Medifast Inc. remains committed to assisting individuals in achieving sustainable weight loss and overall well-being.

Medifast Inc is primarily active in the nutrition and weight management industry.

Medifast Inc faces competition from various companies operating in the health and wellness industry. Some of the main competitors of Medifast Inc include Weight Watchers International Inc, Nutrisystem Inc, Herbalife Nutrition Ltd, and WW International Inc. These companies offer similar products and services aimed at promoting healthy living, weight management, and overall wellbeing. Medifast Inc strives to differentiate itself from its competitors through innovative products, personalized customer support, and a strong focus on scientific research and development. Through continuous efforts, Medifast Inc aims to maintain its position and popularity among consumers in the competitive market.

Medifast Inc, a leading provider of health and wellness products, has a rich history and background. Established in 1980, Medifast has been dedicated to helping people achieve their weight loss and healthy lifestyle goals. With over four decades of experience, the company has developed science-based programs that combine proper nutrition, support, and education to deliver effective and sustainable results. Medifast's commitment to innovation and quality has earned them a strong reputation in the industry. By offering a wide range of nutritional products and personalized support, Medifast continues to empower individuals on their journey towards better health and wellbeing.

Medifast Inc has achieved several significant milestones throughout its history. Some notable achievements include expanding their product lineup to offer a wide range of weight management and nutrition products. The company has also witnessed rapid growth and increased market presence, becoming a leading provider of healthy living products and programs. Medifast Inc has received numerous industry accolades and recognition for their innovative approach to healthy living, including being named as one of Forbes' "100 Most Trustworthy Companies" and earning the Good Housekeeping Seal of Approval. Additionally, Medifast Inc has successfully established a strong network of independent OPTAVIA coaches, empowering individuals to achieve optimal health and financial well-being.

Medifast Inc is primarily present in the United States, Canada, and certain selected international markets.

Medifast Inc represents a strong commitment to health and wellness through its values and corporate philosophy. With a focus on scientific research and evidence-based nutrition, the company offers effective weight loss and management solutions. Medifast prioritizes customer satisfaction, transparency, and integrity, making it a trusted name in the industry. By providing personalized support and a comprehensive approach to well-being, Medifast empowers individuals to achieve their health goals. With its dedication to high-quality products and services, Medifast Inc continues to lead the way in transformative wellness solutions.

Analysts currently set an average price target of 15.30 USD for the Medifast stock (median: 15.30 USD), implying +55.6 % versus the latest price. The consensus is based on 9 analyst ratings.

9 analysts currently rate the Medifast stock: 0 recommend buying, 4 holding and 5 selling. For 2026, analysts expect Medifast to generate revenue of 279.70 M USD and earnings per share of -1.85 USD.

Converted at the current exchange rate, the Medifast share trades at 8.52 EUR (9.83 USD).

The Medifast share (MED) is listed on 7 stock exchanges, including: NYSE (MED), Frankfurt (MDF.F), München (MDF.MU), Düsseldorf (MDF.DU), London (0K05.L), London (0K05.L), SIX (Zürich) (MDF.SW).

Medifast Inc is a leading American company in the health and nutrition industry. The company's business model is based on the production and sale of dietary supplements, meal replacement shakes, snacks, and other products for weight loss and healthy nutrition. Medifast Inc also offers training programs and support for people who want to control their weight and implement a healthy diet. An important part of Medifast Inc's business model is the OPTAVIA® brand. OPTAVIA® is an innovative concept that provides comprehensive support for nutrition and weight loss. The program includes personalized nutritional counseling, access to online tools and resources, and support from a coach. The OPTAVIA® brand is one of Medifast Inc's main sources of revenue and has contributed to the company's growth and expansion. Medifast Inc also offers other brands such as Medifast®, Thrive by Medifast™, and Jason Pharmaceuticals™. Medifast® offers meal replacement shakes, bars, and soups that are intended to promote effective weight loss. Thrive by Medifast™ is a brand based on the principle that a healthy diet is the best foundation for optimal physical and mental health. Jason Pharmaceuticals™ is a brand specializing in the development and marketing of products that support women in various stages of their lives (such as pregnancy, menopause, etc.). Medifast Inc distributes its products and services through various channels such as direct sales, online orders, and distribution partners. The company has an extensive network of over 30,000 independent distribution partners who serve as OPTAVIA® coaches. These coaches are trained nutrition experts who provide their clients with personalized nutrition plans and support in achieving their weight loss goals. Medifast Inc's business model is based on a holistic approach to healthy eating and weight loss. The company is committed to offering high-quality products based on scientific knowledge and providing its customers with comprehensive support in implementing a healthy lifestyle. Medifast Inc has built a strong market position through its commitment to quality and customer satisfaction and is a leading provider of dietary supplements and meal replacement products in the US and the world. Overall, Medifast Inc's business model is focused on high-quality products, personalized support, and a wide range of offerings for customers. Medifast Inc has become an important company in the health and nutrition industry and is dedicated to providing its customers with high-quality and comprehensive support in implementing a healthy lifestyle.

The expected revenue of Medifast is 279.70 M USD. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Medifast is -20.28 M USD. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Medifast is currently -5.33. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Medifast stock.

The price-to-sales ratio (P/S) of Medifast is currently 0.39. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Medifast stock.

The Eulerpool Quality Score for Medifast is 1/10.

The ISIN of Medifast is US58470H1014. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The WKN of Medifast is 889384. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.

The ticker of Medifast is MED. The ticker symbol is used to trade Medifast shares on the stock exchange.

Over the past 12 months, Medifast paid a dividend of 4.95 USD . This corresponds to a dividend yield of about 50.36 %. For the coming 12 months, Medifast is expected to pay a dividend of 9.50 USD.

The current dividend yield of Medifast is 50.36 %.

Medifast pays a dividend, distributed in the months of , , , .

Medifast paid dividends every year for the past 0 years.

For the upcoming 12 months, dividends amounting to 9.50 USD are expected. This corresponds to a dividend yield of 96.68 %.

Medifast is assigned to the 'Non-cyclical consumption' sector.

To receive the latest dividend of Medifast from amounting to 1.65 USD, you needed to have the stock in your portfolio before the ex-date on .

The last dividend was paid out on .

The dividends of Medifast are distributed in USD.

All fundamentals and in-depth analysis of Medifast

Our stock analysis for Medifast stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medifast. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.